文章核心观点 DBV Technologies宣布向法国市场监管机构提交2024年通用注册文件附录，该附录更新了董事会公司治理报告，涉及CEO特殊薪酬，支付需经年度联合股东大会批准 [1][2] 公司动态 - 公司向法国市场监管机构“Autorité des Marchés Financiers”提交2024年通用注册文件附录 [1] - 附录更新董事会公司治理报告，涉及2025年4月30日董事会会议授予CEO的特殊薪酬，支付待2025年6月11日年度联合股东大会批准 [2] - 通用注册文件和附录可在公司网站和AMF网站查看，纸质版可在公司总部免费获取 [3] 公司介绍 - 临床阶段生物制药公司，开发食物过敏和其他免疫疾病治疗方案，专注用Viaskin平台解决食物过敏问题 [4] - 食物过敏由过敏免疫反应引起，症状多样，Viaskin平台通过经皮免疫疗法（EPIT™）引入生物活性化合物，重新训练免疫系统脱敏 [4] - 公司致力于改善食物过敏患者护理，食物过敏项目包括Viaskin Peanut在花生过敏幼儿和儿童中的临床试验 [4] - 公司总部位于法国，北美业务在新泽西州，普通股在泛欧巴黎证券交易所交易，美国存托股票在纳斯达克资本市场交易 [5] 联系方式 - 投资者联系Katie Matthews，邮箱katie.matthews@dbv-technologies.com [6] - 媒体联系Angela Marcucci，邮箱angela.marcucci@dbv-technologies.com [6]

Châtillon, France, May 15, 2025 Combined General Meeting of June 11, 2025 Procedures for Obtaining Information and Preparatory Documents for the Combined General Meeting DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company (the “Company”), will hold its Combined General Meeting (the “General Meeting”) on June 11, 2025, at 02:00 p.m. CEST (08:00 a.m EST) at the Company’s headquarters located at IRO Building, 107 Avenue de la République, ...

Châtillon, France, May 15, 2025 Combined General Meeting of June 11, 2025 Procedures for Obtaining Information and Preparatory Documents for the Combined General Meeting DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company (the “Company”), will hold its Combined General Meeting (the “General Meeting”) on June 11, 2025, at 02:00 p.m. CEST (08:00 a.m EST) at the Company’s headquarters located at IRO Building, 107 Avenue de la République, ...

Châtillon, France, May 5, 2025 DBV Technologies to Participate in the Citizens JMP Life Sciences Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced Daniel Tassé, Chief Executive Officer, will participate in a fireside chat at the Citizens JMP Life Sciences Conference on Wednesday, May 7, 2025, at 11:00am ET, in New York, NY. A live webcast of the fireside chat can be accessed here, and will also be availab ...

Châtillon, France, April 30, 2025   DBV Technologies Reports First Quarter 2025 Financial Results DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today reported financial results for the First Quarter of 2025. The quarterly and three months financial statements were approved by the Board of Directors on April 30, 2025. Financial Highlights for the First Quarter Ended March 31, 2025 The Company’s interim conden ...